Urinary neopterin, serum retinol,α-tocopherol and homocysteine in breast cancer patients during treatment with bevacizumab and chemotherapy

Pteridines

Volumn 21, Issue 4, 2010, Pages 87-93

  Melichar, Bohuslav ^a,b   Kalábová, Hana ^b   Krcmová, Lenka ^b   Kašparová, Markéta ^b   Plíšek, Jirí ^b   Hyšpler, Radomír ^b   Študentová, Hana ^a   Zezulová, Michaela ^a   Holecková, Petra ^b   Pecka, Miroslav ^b   Solichová, Dagmar ^b  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Bevacizumab; C reactive protein; Homocysteine; Neopterin; tocopherol

Indexed keywords

ALPHA TOCOPHEROL; BEVACIZUMAB; C REACTIVE PROTEIN; CARBOPLATIN; DOCETAXEL; HOMOCYSTEINE; NEOPTERIN; PACLITAXEL; RETINOL;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE RESPONSE; IMMUNOCHEMISTRY; INFLAMMATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; URINE LEVEL; VITAMIN BLOOD LEVEL;

EID: 79952170629     PISSN: 09334807     EISSN: 21954720     Source Type: Journal    
DOI: 10.1515/pteridines.2010.21.1.87     Document Type: Article

References (46)

1. Steinberg D. Oxidative modification of LDL and atherogenesis. Circulation 1997;95:1062-1071.
2. Keaney JF, Guo Y, Cunningham D, Swaery GT, Xu A, Vita JA. Vascular incorporation of alpha-tocopherol prevents endothelial dysfunction due to oxidized LDL by inhibiting protein kinase C stimulation. J Clin Invest 1996;98:386-394.
3. Salonen JT, Nyyssonen K, Salonen R, et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000;248:377-386.
4. Ridker P M. Novel risk factors and markers for coronary disease. Adv Intern Med 2000;45:391-419.
5. Nabholtz JM, Gligorov J. Cardiovascular safety profiles of aromatase inhibitors. A comparative review. Drug Safety 2006;29:785-801.
6. Esteva FJ, Hortobagyi GN. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast 2006;15:301-312.
7. Hurwitz H, Febrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
8. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103- 2111.
9. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676.
10. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008;19:927-934.
11. Hillege HL, Fidler V, Diercks GFH, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777-1782.
12. Melichar B, Kalabova H, Krcmova L, et al. Serum homocysteine, cholesterol, retinol, alpha-tocopherol, glycosylated hemoglobin and inflammatory response during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin. Anticancer Res 2009;29:4813-4820.
13. Urbanek L, Solichova D, Melichar B, Dvorak J, Svobodova I, Solich P. Optimization and validation of a high performance liquid chromatography method for the simultaneous determination of vitamins A and E human serum using monolithic column and diode-array detection. Anal Chim Acta 2006;573-574:267-272.
14. Melichar B, Solichova D, Melicharova K, Malirova E, Cermanova M, Zadak Z. Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers 2006;21:190-198.
15. Melichar B, Kalábová H, Krmová L, et al. Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma. Anticancer Res 2009;29:3337-3346.
16. Murr C, Berant A, Widschwendter M, Heim K, Schröcksnadel H, Fuchs D. Neopterin is an independent prognostic variable in females with breast cancer. Clin Chem 1999;45:1998-2004.
17. Sarwar AB, Sarwar A, Rosen BD, Nasir K. Measuring subclinical atherosclerosis:is homocysteine relevant? Clin Chem Lab Med 2007;45:1667- 1677.
18. Wierzbicki A S. Homocysteine and cardiovascular disease: A review of the evidence. Diab Vasc Dis Res 2007;4:143-149.
19. Schroecksnadel K, Frick B, Fiegl M, Winkler C, Denz HA, Fuchs D. Hyperhomocysteinamia and immune activation in patients with cancer. Clin Chem Lab Med 2007;45:47-53.
20. Sun CF, Haven TR, Wu TL, Tsao KC, Wu JT. Serum total homocysteine increases with the rapid proliferation rate of tumor cells and declines upon cell death: a potential new tumor marker. Clin Chim Acta 2002;321:55-62.
21. Wu LL, Wu JT. Hyperhomocysteinemia is risk factor for cancer and a new potential tumor marker. Clin Chim Acta 2002;322:21-28.
22. Schroecksnadel K, Frick B, Wirleitner B, Schennach H, Fuchs D. Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells. Clin Exp Immunol 2003;134:53-56.
23. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-1908.
24. Ridker PM, Hennekens CH, Buring JE, Rifai N. Creactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
25. Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-2610.
26. Melichar B, Solichová D, Freedman RS. Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer 2006;16:240-252.
27. Reibnegger G, Fuchs D, Fuith LC, et al. Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detect Prev 1991;15:483-490.
28. Melichar B, Solichova D, Melicharova K, Cermanova M, Urminska H, Ryska A. Systemic immune activation, anemia and thrombocytosis in breast cancer patients treated by doxorubicin and paclitaxel. Pteridines 2006;17:107-114.
29. Melichar B, Urbanek L, Krcmova L, et al. Urinary neopterin, hemoglobin and peripheral blood cell counts in breast carcinoma patients treated with dose-dense chemotherapy. Anticancer Res 2008;28:2389-2396.
30. Grammer TB, Fuchs D, Boehm BO, Winkelmann BR, Maerz W. Neopterin as a predictor of total and cardiovascular mortality in individuals undergoing angiography in the Ludwigshafen Risk and Cardiovascular Health Study. Clin Chem 2009;55:1135-1146.
31. Melichar B, Jandik P, Krejsek J, et al. Mitogeninduced lymphocyte proliferation and systemic immune activation in cancer patients. Tumori 1996;82:218-220.
32. Melichar B, Savary C, Kudelka AP, et al. Lineagenegative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis. Clin Cancer Res 1998;4:799-809.
33. Melichar B, Nash MA, Lenzi R, Platsoucas CD, Freedman RS. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumor infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol 2000;119:19-27.
34. Melichar B, Touskova M, Solichova D, Kralickova P, Kopecky O. CD4+ T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. Scand J Clin Lab Inv 2001;61:363-370.
35. Debier C, Larondelle Y. Vitamins A and E: metabolism, roles and transfer to offspring. Br J Nutr 2005;93:153-174.
36. Delanian S, Porcher R, Balla-Mekias S, Lefaix JL. Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis. J Clin Oncol 2003;21:2545-2550.
37. Pace A, Savarese A, Picardo M, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 2003;21:927-931.
38. Faure H, Coudray C, Mousseau M, et al. 5- Hydroxymethyluracil excretion, plasma TBARS and plasma antioxidant vitamins in adriamycintreated patients. Free Radic Biol Med 1996;20:979- 983.
39. Jonas RC, Puckett AB, Jones DP, et al. Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr 2000;72:181-189.
40. High KP, Legault C, Sinclair JA, Cruz J, Hill K, Hurd DD. Low plasma concentrations of retinol and alpha-tocopherol in hematopoietic stem cell transplant recipients: the effect of mucositis and the risk of infection. Am J Clin Nutr 2002;76:1358-1366.
41. Faber M, Coudray C, Hida H, Mousseau M, Favier A. Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin. A preliminary study. Biol Trace Elem Res 1995;47:117-123.
42. McMillan DC, Talwar D, Sattar N, Underwood M, O'Reilly DSJ, McArdle C. The relationship between reduced vitamin antioxidant concentrations and the systemic inflammatory response in patients with common solid tumours. Clin Nutr 2002;21:161-164.
43. McMillan DC, Sattar N, Talwar D, O'Reilly J, McArdle CS. Changes in micronutrient concentrations following anti-inflammatory treatment in patients with gastrointestinal cancer. Nutrition 2000;16:425-428.
44. Mayland C, Allen KR, Degg TJ, Bennet M. Micronutrient concentrations in patients with malignant disease: effect of the inflammatory response. Ann Clin Biochem 2004;41:138-141.
45. Melichar B, Kalabova H, Krcmova L, et al. Serum alpha-tocopherol, retinol and neopterin during paclitaxel/carboplatin chemotherapy. Anticancer Res 2007;27:4397-4401.
46. Murr C, Winklhofer-Roob BM, Schroecksnadel K, et al. Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease. Atherosclerosis 2009;202:543-549